Initiated Buy X

WVE Wave Life Sciences

Jefferies

$26

Upgrades Outperform Strong Buy X

WVE Wave Life Sciences

Raymond James

$22

Resumed Overweight X

WVE Wave Life Sciences

JP Morgan

$10 $13

Initiated Buy X

WVE Wave Life Sciences

B. Riley Securities

$11

Initiated Overweight X

WVE Wave Life Sciences

JP Morgan

$10

Initiated Overweight X

WVE Wave Life Sciences

Wells Fargo

$11

Upgrades Mkt Perform Outperform X

WVE Wave Life Sciences

Leerink Partners

$5 $12

Initiated Outperform X

WVE Wave Life Sciences

Raymond James

$7

Downgrades Buy Hold X

WVE Wave Life Sciences

Jefferies

$7 $5

Initiated Market Perform X

WVE WAVE Life Sciences

Cowen

Reiterated Buy X

WVE WAVE Life Sciences

H.C. Wainwright

$49 $33

Initiated Buy X

WVE WAVE Life Sciences

Stifel

$56

Initiated Buy X

WVE WAVE Life Sciences

H.C. Wainwright

$49

Reiterated Buy X

WVE WAVE Life Sciences

Mizuho

$34 $65

WVE  WAVE Life Sciences Ltd.

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.